Faculty

	Eric D. Donnenfeld, MD (Chair) Clinical Professor of Ophthalmology New York University Langone Medical Center New York, New York Founding Partner Ophthalmic Consultants of Long Island and Connecticut Garden City, New York
	Marjan Farid, MD Professor of Ophthalmology Director of Cornea, Cataract, and Refractive Surgery Vice Chair of Ophthalmic Faculty Gavin Herbert Eye Institute University of California, Irvine Irvine, California
	Nicole R. Fram, MD Clinical Instructor of Ophthalmology Stein Eye Institute University of California, Los Angeles Managing Partner Advanced Vision Care Los Angeles, California
	Preeya K. Gupta, MD Managing Director Triangle Eye Consultants Raleigh, North Carolina Adjunct Associate Professor of Ophthalmology Cornea, Cataract, & Refractive Surgery Tulane University New Orleans, Louisiana

Disclosure Policy

MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.

Faculty

Eric D. Donnenfeld, MD, is a consultant for Alcon, Allegro Ophthalmics, LLC, Allergan, Aurion Biotechnologies, Avellino, Bausch & Lomb Incorporated, BlephEx, BVI, CorneaGen, Covalent, Crystilex, Dompé US, Inc, ELT Sight, EyePoint Pharmaceuticals, Foresight Labs, LLC, Glaukos Corporation, Ivantis Inc, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Katena Products, Inc, LacriPen, LayerBio, Inc, LensGen, Mati Therapeutics, Inc, Melt Pharmaceuticals, Merck & Co., Inc, Mimetogen Pharmaceuticals, Nanowafer, NovaBay Pharmaceuticals, Inc, Novaliq GmbH, Novartis Pharmaceuticals Corporation, OcuHub LLC, Oculis, Odyssey Medical, Inc, Omega Ophthalmics, Omeros Corporation, Oyster Point Pharma, Inc, Pfizer Inc, PogoTec, PRN, Rapid Pathogen Screening, Inc, Rayner Intraocular Lenses Limited, ReTEAR, Inc, Shire, Strathspey Crown, Sun Pharmaceutical Industries, Inc, Surface Pharmaceuticals Inc, Tarsus Pharmaceuticals, Inc, TearLab Corporation, TearScience, Thea Pharmaceuticals Limited, Veracity Innovations LLC, Versant Ventures, Visionary Ventures, Visus Therapeutics, and Zeiss; and has stock options in Aurion Biotechnologies, Avedro, Inc, CorneaGen, Covalent, Crystilex, ELT Sight, EyePoint Pharmaceuticals, Glaukos Corporation, Ivantis Inc, LacriPen, LayerBio, Inc, LensGen, Mati Pharmaceuticals, Inc, Melt Pharmaceuticals, Mimetogen Pharmaceuticals, NovaBay Pharmaceuticals, Inc, OcuHub LLC, Oculis, Orasis Pharmaceuticals, PogoTec, Rapid Pathogen Screening, Inc, Rayner Intraocular Lenses Limited, ReTEAR, Inc, Strathspey Crown, Surface Pharmaceuticals Inc, Tarsus Pharmaceuticals, Inc, TearLab Corporation, Veracity Innovations LLC, Versant Ventures, Visionary Ventures, and Visus Therapeutics.

Marjan Farid, MD, is a consultant for AcuFocus, Inc*, Alcon, Aldeyra Therapeutics, Allergan, Bausch & Lomb Incorporated, Bio-Tissue, Carl Zeiss Meditec, Inc, CorneaGen, Dompé US, Inc*, Glaukos Corporation*, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, Orasis Pharmaceuticals, Oyster Point Pharma, Inc, Sun Pharmaceutical Industries, Inc, and Tarsus Pharmaceuticals, Inc; is an advisory board member of AcuFocus, Inc*, Alcon, Aldeyra Therapeutics, Allergan, Bausch & Lomb Incorporated, Bio-Tissue, Carl Zeiss Meditec, Inc, CorneaGen, Dompé US, Inc*, Glaukos Corporation*, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, Orasis Pharmaceuticals, Oyster Point Pharma, Inc, Sun Pharmaceutical Industries, Inc, and Tarsus Pharmaceuticals, Inc; and has stocks or stock options in Kala Pharmaceuticals.

Nicole R. Fram, MD, is a consultant for Alcon, Aldeyra Therapeutics, Aurion Biotechnologies, CorneaGen, Glaukos Corporation, Johnson & Johnson Vision Care, Inc, RxSIGHT, and Zeiss; is an advisory board member of Aurion Biotechnologies, CorneaGen, Johnson & Johnson Vision Care, New World Medical, Inc, Ocular Science, and Orasis Pharmaceuticals; is on the speakers bureau for Alcon and Johnson & Johnson Vision Care; and is a contracted researcher for Ocular Therapeutix, Inc, and Zeiss.

Preeya K. Gupta, MD, is a consultant for Alcon, Aldeyra Therapeutics, Allergan, Azura Ophthalmics, Carl Zeiss Meditec, Inc, Expert Opinion MD, Hanall Biopharma, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, New World Medical, Inc, Novartis Pharmaceuticals Corporation, Ocular Science, Ocular Therapeutix, Inc, Orasis Pharmaceuticals, Oyster Point Pharma, Inc, Sight Sciences, SpyGlass Ophthalmics, Sun Pharmaceutical Industries, Inc, Surface Pharmaceuticals Inc, TearClear, TearLab Corporation, TissueTech, Inc, and Visionology; has stock options that have not been exercised in Azura Ophthalmics, Expert Opinion MD, Orasis Pharmaceuticals, SpyGlass Ophthalmics, Surface Pharmaceuticals Inc, TearClear, and Visant Medical, Inc; and has stocks or stock options in Oyster Point Pharma, Inc, Tarsus Pharmaceuticals, Inc, and Visionology.

* The financial relationship existed during the past 24 months but has now ended.

Peer Reviewer

This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.

Planners, Managers, and Writers

MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.